Cargando…

Drug survival of anti‐TNF agents compared with vedolizumab as a second‐line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers

BACKGROUND: Comparisons of second‐line anti‐tumour necrosis factor (TNF) agents and vedolizumab are sparse. AIM: To evaluate the effectiveness of anti‐TNF agents compared to vedolizumab as second‐line biologics in inflammatory bowel disease (IBD). METHODS: A propensity score‐matched cohort was creat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rundquist, Sara, Sachs, Michael C., Eriksson, Carl, Olén, Ola, Montgomery, Scott, Halfvarson, Jonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Anti‐tnfs Compared with Vedolizumab as Second‐line Biologics in IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898922/ https://www.ncbi.nlm.nih.gov/pubmed/33340426 http://dx.doi.org/10.1111/apt.16193

Ejemplares similares

Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
por: Volkers, Adriaan, et al.
Publicado: (2022)

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
por: Bergqvist, Viktoria, et al.
Publicado: (2022)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease
por: Dulai, Parambir S., et al.
Publicado: (2019)

Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study
por: Everhov, Åsa H., et al.
Publicado: (2022)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Limited long‐term treatment persistence of first anti‐TNF therapy in 538 patients with inflammatory bowel diseases: a 20‐year real‐world study
por: Blesl, Andreas, et al.
Publicado: (2021)

Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study
por: Pugliese, Daniela, et al.
Publicado: (2022)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register
por: Forss, Anders, et al.
Publicado: (2019)

Earnings during adulthood in patients with childhood‐onset inflammatory bowel disease: a nationwide population‐based cohort study
por: Malmborg, Petter, et al.
Publicado: (2022)

A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II
por: Lenti, Marco Vincenzo, et al.
Publicado: (2021)

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
por: Ye, Lingna, et al.
Publicado: (2020)

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
por: Eriksson, Carl, et al.
Publicado: (2021)

60 Seconds
Publicado: (2009)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register
por: Thunberg, Joel, et al.
Publicado: (2022)

Association Between Inflammatory Bowel Disease and Psychiatric Morbidity and Suicide: A Swedish Nationwide Population-Based Cohort Study With Sibling Comparisons
por: Ludvigsson, Jonas F, et al.
Publicado: (2021)

Women’s Earnings are more Affected by Inflammatory Bowel Disease than Men’s: A Register-Based Swedish Cohort Study
por: Everhov, Åsa H, et al.
Publicado: (2020)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Giving anti-VEGF injections: an update from Burundi
por: Niyonzima, Jean Claude
Publicado: (2023)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
por: Visuri, Isabella, et al.
Publicado: (2023)

The illusion of universality: The use of Nordic population registers in studies of migration, employment and health
por: Gauffin, Karl
Publicado: (2020)

Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study
por: Lochhead, Paul, et al.
Publicado: (2020)

Mixing with Medics
por: Smith, Matthew
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kubjc0pdr5jqtum9ao7sgatbu5